Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

Poor Sleep Associated With Cannabis and Alcohol Use, Dietary Approaches in MS, Noninvasive Brain Stimulation Effective in Alzheimer

Poor Sleep Associated With Cannabis and Alcohol Use, Dietary Approaches in MS, Noninvasive Brain Stimulation Effective in Alzheimer

NeurologyLive® Staff

November 5th 2022

Neurology News Network for the week ending November 5, 2022. [WATCH TIME: 3 minutes]

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers

October 29th 2022

Neurology News Network for the week ending October 28, 2022. [WATCH TIME: 4 minutes]

Positive Interim Report on Fosgonimeton, Lower ASPECTS Scores Impact Efficacy of EVT, FDA Extends Review of Tofersen

Positive Interim Report on Fosgonimeton, Lower ASPECTS Scores Impact Efficacy of EVT, FDA Extends Review of Tofersen

NeurologyLive® Staff

October 22nd 2022

Neurology News Network for the week ending October 22, 2022. [WATCH TIME: 4 minutes]

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

NeurologyLive® Staff

October 15th 2022

Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

NeurologyLive® Staff

October 8th 2022

Neurology News Network for the week ending October 8, 2022. [WATCH TIME: 3 minutes]

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

NeurologyLive® Staff

October 1st 2022

Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

NeurologyLive® Staff

September 24th 2022

Neurology News Network for the week ending September 24, 2022. [WATCH TIME: 4 minutes]

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

NeurologyLive® Staff

September 17th 2022

Neurology News Network for the week ending September 17, 2022. [WATCH TIME: 4 minutes]

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

NeurologyLive® Staff

September 10th 2022

Neurology News Network for the week ending September 10, 2022. [WATCH TIME: 4 minutes]

FDA Approves Auotinjector for Status Epilepticus, Penumbra System Removes Clots in Ischemic Stroke, Tobacco Use Correlated With Cognitive Decline

FDA Approves Auotinjector for Status Epilepticus, Penumbra System Removes Clots in Ischemic Stroke, Tobacco Use Correlated With Cognitive Decline

NeurologyLive® Staff

September 3rd 2022

Neurology News Network for the week ending September 3, 2022. [WATCH TIME: 4 minutes]

Remote Ischemic Conditioning Improves Post Stroke Outcomes, Opiate Use High in Idiopathic Intracranial Hypertension, Drug Resistant Epilepsy and Increased Mortality

Remote Ischemic Conditioning Improves Post Stroke Outcomes, Opiate Use High in Idiopathic Intracranial Hypertension, Drug Resistant Epilepsy and Increased Mortality

NeurologyLive® Staff

August 27th 2022

Neurology News Network for the week ending August 27, 2022. [WATCH TIME: 4 minutes]

Results of VISIONARY-MS Study Released, Analysis Complete for Concussion Therapy OXE103, Chronic Kidney Disease Associated With Intracerebral Hemorrhage

Results of VISIONARY-MS Study Released, Analysis Complete for Concussion Therapy OXE103, Chronic Kidney Disease Associated With Intracerebral Hemorrhage

NeurologyLive® Staff

August 20th 2022

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

Stigma Adds to Depressive Symptoms in Epilepsy, Parkinson Disease and Diabetes Show Increased Neuroaxonal Damage, ICER Publishes Report on ALS Treatments

Stigma Adds to Depressive Symptoms in Epilepsy, Parkinson Disease and Diabetes Show Increased Neuroaxonal Damage, ICER Publishes Report on ALS Treatments

NeurologyLive® Staff

August 13th 2022

Neurology News Network for the week of August 13, 2022. [WATCH TIME: 4 minutes]

Severe Preeclampsia Linked With Neuroinflammation, Neurofilament Light Associated With Memory Function, Discrimination Effects on Cognition

Severe Preeclampsia Linked With Neuroinflammation, Neurofilament Light Associated With Memory Function, Discrimination Effects on Cognition

NeurologyLive® Staff

August 6th 2022

Neurology News Network for the week ending August 6, 2022. [WATCH TIME: 4 minutes]

FDA Accepts NDA for Tofersen, Serious Falls Increased With Hypnotic Medications, Racial Disparities in Sleep of Pregnant Women

FDA Accepts NDA for Tofersen, Serious Falls Increased With Hypnotic Medications, Racial Disparities in Sleep of Pregnant Women

NeurologyLive® Staff

Neurology News Network for the week ending July 30, 2022. [WATCH TIME: 4 minutes]

CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218

CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218

NeurologyLive® Staff

Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]

Apitegromab Continues Positive Efficacy in SMA, Alzheimer Disease Risk Reduced Through Lifestyle Factors, Depressive Trajectories Predict Stroke Risk

Apitegromab Continues Positive Efficacy in SMA, Alzheimer Disease Risk Reduced Through Lifestyle Factors, Depressive Trajectories Predict Stroke Risk

NeurologyLive® Staff

Neurology News Network for the week ending July 16, 2022. [WATCH TIME: 4 minutes]

FDA Grants Priority Review for Lecanemab, FDA AdComm to Reconvene on AMX0035, Tolebrutinib Trials Suspended Over Safety

FDA Grants Priority Review for Lecanemab, FDA AdComm to Reconvene on AMX0035, Tolebrutinib Trials Suspended Over Safety

NeurologyLive® Staff

Neurology News Network for the week ending July 9, 2022. [WATCH TIME: 4 minutes]

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

NeurologyLive® Staff

Neurology News Network for the week ending July 2, 2022. [WATCH TIME: 4 minutes]

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

NeurologyLive® Staff

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

NeurologyLive® Staff

Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

NeurologyLive® Staff

Neurology News Network for the week ending June 11, 2022. [WATCH TIME: 3 minutes]

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

NeurologyLive® Staff

Neurology News Network for the week ending May 28, 2022.

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

NeurologyLive® Staff

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

NeurologyLive® Staff

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

NeurologyLive® Staff

Neurology News Network for the week ending May 7, 2022. [WATCH TIME: 4 minutes]

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

NeurologyLive® Staff

April 30th 2022

Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

NeurologyLive® Staff

April 23rd 2022

Neurology News Network for the week ending April 23, 2022. [WATCH TIME: 3 minutes]

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

NeurologyLive® Staff

April 16th 2022

Neurology News Network for the week ending April 16, 2022 [WATCH TIME: 3 minutes]

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

NeurologyLive® Staff

Neurology News Network for the week ending April 9, 2022. [WATCH TIME: 4 minutes]

<1 2 3 4 5 6 7 8 9 10 >

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.